#1 Clinical Trials Search in Europe

Tiemonium Methylsulphate

This article discusses the use of Tiemonium Methylsulphate, in combination with Colchicine, in clinical trials for the treatment of calcium pyrophosphate deposition disease (CPPD). The study aims to evaluate the effectiveness of this drug combination in managing inflammation and symptoms associated with CPPD, a condition that affects joints and can cause arthritis-like symptoms.

Table of Contents

What is Tiemonium Methylsulphate?

Tiemonium Methylsulphate is a medication that belongs to a class of drugs known as anticholinergics. It is also referred to as Tiemonium metilsulfate in some contexts[1]. This medication is often used in combination with other drugs to treat various medical conditions, particularly those affecting the musculoskeletal system.

Medical Conditions Treated

While the primary focus of the clinical trial data is on a condition called calcium pyrophosphate deposition disease (CPPD), Tiemonium Methylsulphate is being studied in combination with other medications for its potential benefits in treating this condition[1]. CPPD is a form of arthritis caused by the buildup of calcium pyrophosphate crystals in the joints, leading to inflammation and pain.

Combination with Other Medications

In the clinical trial, Tiemonium Methylsulphate is being studied in combination with Colchicine. This combination is being compared to other treatment options for CPPD, including:

  • Methylprednisolone: A corticosteroid used to reduce inflammation
  • Colchicine: A medication commonly used to treat gout and other inflammatory conditions
  • Hydroxychloroquine: An antimalarial drug also used to treat certain autoimmune diseases
  • Methotrexate (MTX): A medication used to treat various inflammatory conditions and certain types of cancer

The combination of these medications is being studied to determine the most effective treatment approach for patients with CPPD[1].

Administration and Dosage

The specific dosage of Tiemonium Methylsulphate is not provided in the clinical trial data. However, the combination medication (Colchicine with Tiemonium Methylsulphate) is administered as follows:

  • 1 mg tablets
  • Taken once daily after breakfast
  • The dosage may be adjusted to 1 or ½ tablet, depending on individual tolerance

It’s important to note that this dosage information is specific to the clinical trial and may not reflect the typical dosage for all patients[1].

Potential Benefits

While the specific benefits of Tiemonium Methylsulphate are not directly stated in the clinical trial data, the combination therapy is being studied for its potential to:

  • Reduce inflammation in the joints affected by CPPD
  • Improve patient-reported outcomes and pain levels
  • Decrease calcium crystal deposition in the joints
  • Reduce synovitis (inflammation of the synovial membrane in the joints)

These potential benefits are being evaluated through various measures, including changes in pain scores, functional assessments, and imaging studies[1].

Important Considerations

When considering treatment with Tiemonium Methylsulphate or any medication, it’s essential to keep the following points in mind:

  • Always follow your doctor’s instructions regarding dosage and administration.
  • Inform your healthcare provider about any other medications you’re taking, as drug interactions may occur.
  • Be aware of potential side effects and report any unusual symptoms to your doctor.
  • Regular follow-ups and monitoring may be necessary to assess the medication’s effectiveness and safety.

As with any medication, the use of Tiemonium Methylsulphate should be carefully considered by your healthcare provider based on your individual medical history and current condition[1].

Aspect Details
Study Type Phase 2/3 clinical trial
Condition Calcium pyrophosphate deposition disease (CPPD)
Treatment Tiemonium Methylsulphate in combination with Colchicine
Primary Objective Evaluate effect on synovial membrane inflammation
Secondary Objectives Assess changes in patient-reported outcomes, pain, and ultrasound findings
Eligibility Patients ≥55 years old meeting CPPD classification criteria
Key Exclusions Active infections, venous thromboembolism history, uncontrolled medical conditions
Duration 24 weeks

FAQ

  • What is calcium pyrophosphate deposition disease (CPPD)? CPPD is a condition where calcium pyrophosphate crystals build up in the joints, causing inflammation and symptoms similar to arthritis. It can affect various joints in the body and may lead to pain, swelling, and reduced mobility.
  • How is Tiemonium Methylsulphate being used in the clinical trial? Tiemonium Methylsulphate is being used in combination with Colchicine as part of the treatment regimen. The trial is comparing this combination to other standard treatments for CPPD to evaluate its effectiveness in managing the disease.
  • What are the main objectives of the clinical trial? The main objectives include evaluating the effect of the treatment on inflammation in the synovial membrane, assessing changes in patient-reported outcomes and pain, and determining changes in calcium crystal deposition and synovitis through ultrasound examination.
  • Who is eligible to participate in this clinical trial? Eligible participants are male and female patients aged 55 years or older who meet the 2023 ACR/EULAR classification criteria for CPPD disease. They must have specific clinical presentations of CPPD, such as polyarticular involvement of small joints or recurrent effusion in large joints.
  • What are some of the exclusion criteria for the trial? Exclusion criteria include patients with active infections, a history of venous thromboembolism, significant uncontrolled medical conditions, recent major cardiovascular events, and certain laboratory abnormalities. Patients with other types of arthritis or conditions that may cause arthritis are also excluded.

Ongoing Clinical Trials on Tiemonium Methylsulphate

  • Study of colchicine to improve insulin sensitivity in adults with type 1 diabetes who have low-grade inflammation

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Poland

  • Study on Baricitinib for Patients with Calcium Pyrophosphate Deposition Disease (CPPD) Using Methotrexate Sodium and Drug Combination

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Colchicine and Opium for Preventing Heart and Kidney Issues in Patients with Moderate Chronic Kidney Disease

    Recruiting

    3 1 1
    Investigated drugs:
    Spain

  • Study on Colchicine and Tiemonium Methylsulphate for Reducing Atherosclerosis in Cancer Patients Undergoing Immune Therapy

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Calcium pyrophosphate deposition disease (CPPD): A condition where calcium pyrophosphate crystals accumulate in joints, causing inflammation and symptoms similar to arthritis.
  • Synovial membrane: The soft tissue lining the inside of joints, which can become inflamed in conditions like CPPD.
  • Tiemonium Methylsulphate: A medication used in combination with Colchicine in this clinical trial to treat CPPD.
  • Colchicine: An anti-inflammatory medication commonly used to treat gout and other crystal-induced arthropathies.
  • Ultrasound examination: A non-invasive imaging technique used to visualize internal body structures, including joints and soft tissues.
  • Synovitis: Inflammation of the synovial membrane in joints.
  • ACR/EULAR classification criteria: A set of standardized criteria developed by the American College of Rheumatology and European League Against Rheumatism to classify rheumatic diseases.
  • Polyarticular involvement: The condition affecting multiple joints simultaneously.
  • Joint effusion: An accumulation of fluid within a joint space, often causing swelling and discomfort.
  • Venous thromboembolism: A condition where blood clots form in the veins, potentially leading to serious complications.

References

  1. http://clinicaltrials.eu/trial/study-on-baricitinib-for-patients-with-calcium-pyrophosphate-deposition-disease-cppd-using-methotrexate-sodium-and-drug-combination/